AstraZeneca selects IntraLinks as standard Internet hub for clinical trials

“In clinical trials that take years and cost millions of dollars, every day saved can result in therapeutic alternatives for patients and significant cost savings for the company," said Glenn Go



In clinical trials that take years and cost millions of dollars, every day saved can result in therapeutic alternatives for patients and significant cost savings for the company," said Glenn Gormley, Vice President, U.S. Clinical Development, AstraZeneca. "IntraLinks has emerged as one solution that could produce concrete time and cost savings, and we are now implementing its use in clinical trials."

"Through the use of IntraLinks's services, we will greatly enhance information exchange among IRBs, CROs, investigators and trial managers, and hope to accelerate the process significantly," Gormley said. "We anticipate that the results of this initiative will be enormously successful.

Pharmaceutical companies use IntraLinks's Internet-based services to communicate and deliver documentation pertaining to clinical trials, drug licensing, mergers and acquisitions and other complex, high-value business processes that require secure exchange of information across enterprise boundaries. IntraLinks provides a neutral third party environment that is fully hosted and includes 24-hour service and support. IntraLinks's service was designed to comply with FDA and ICH computer system validation requirements.

Within the pharmaceutical community, market-leaders like AstraZeneca are continuously seeking innovative ways to reduce the time necessary to bring drugs to market, said Richard Jenkins, General Manager of Life Sciences at IntraLinks. IntraLinks is committed to providing the pharmaceutical industry with the service and technology needed to speed clinical trials through our drug development hub.